RIGL250117C27000
- 0.00
- 0.000.00%
Rigel Pharmaceuticals Newsroom
Is There An Opportunity With Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 40% Undervaluation?
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57
Rigel Pharmaceuticals Reports Initial Efficacy, Safety Data From Cancer Drug Study
Rigel Pharmaceuticals Highlights Initial Data From Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated...
B.Riley Financial Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $27
Rigel Pharmaceuticals Is Maintained at Neutral by B. Riley Securities
Rigel Pharmaceuticals Price Target Raised to $27.00/Share From $17.00 by B. Riley Securities
AppLovin, MicroStrategy, and 28 Other Stocks That Could Be Bubbles
Rigel Pharmaceuticals Says Its R289 Hematology Drug Candidate Receives Fast-Track Designation From US FDA
Express News | Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
How Much Upside Is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $23
Express News | Citigroup raised Rigel Pharmaceuticals' target stock price from $40.00 to $49.00.
Rigel Pharmaceuticals Analyst Ratings
Rigel to Present at the Jefferies London Healthcare Conference
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Raises Target Price to $49
Citi Sees Good Things Ahead for Rigel -- Market Talk
Institutional Investors Are Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Biggest Bettors and Were Rewarded After Last Week's US$139m Market Cap Gain
Rigel Pharmaceuticals Up Over 36%, on Track for Highest Close Since May 2022 -- Data Talk